AARDAardvark Therapeutics, Inc. Common Stock
The Read
AARD stock has shown extreme volatility around clinical trial updates, plunging about 28.
The schedule
- Tue10Nov
- Sun14Feb
- Sun16May
- Tue10Aug
Past
- Tue11Aug
Actual outcome: Bull · $6.41 at outcome
Aardvark Therapeutics reported Q2 2026 earnings that exactly met analyst expectations with an EPS of -$0.99. The stock rallied because the company announced it will assess unblinded Phase 3 HERO and open-label extension data for ARD-101 in Prader-Willi Syndrome (PWS) in the third quarter. Investors reacted positively to this pipeline update, as the impending data readout provides a major near-term catalyst for determining the drug's regulatory next steps.
Quarterly earnings report expected to heavily feature updates on the paused Phase 3 HERO trial and the ensuing cash burn trajectory.
- Thu25Jun
Actual outcome: Bull · $5.18 at outcome
Aardvark Therapeutics faced ongoing investor scrutiny and legal investigations regarding the March 2026 clinical pause of its Phase 3 HERO trial for ARD-101. Despite this negative backdrop, the stock surged past the $4.00 bull target to close at $5.06, indicating that the highly anticipated strategic pipeline update provided enough positive clarity and viable pivot opportunities to reassure investors.
Management's highly anticipated update on the status of the paused Phase 3 HERO trial for ARD-101 and potential strategic pivots.
- Mon23Mar
Actual outcome: Bear · $3.64 at outcome
AARD reported in-line Q4 2025 EPS of -$0.81, meeting expectations exactly. However, the stock fell 10.6% and broke below the bear floor as focus shifted to the company's cash runway and financing strategy. The sell-off was driven by investor concerns over potential near-term dilution and the capital required to fund operations through the upcoming Phase 3 readout.
Focus on cash burn and management commentary regarding the financing strategy for the upcoming Phase 3 readout.
